MGLL and Miyoshi myopathy: Collectively, the results presented in this study extend our and others previous findings on the role of the endocannabinoid system in the skeleton [3, 19, 27, 28], and support the hypothesis that MAGL inhibitors such as JZL184 are ineffective in reducing neither tumour growth nor osteolytic bone damage caused by haematological malignancies such as MM.